We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
- Authors
Olincy, Ann; Harris, Josette G; Johnson, Lynn L; Pender, Vicki; Kongs, Susan; Allensworth, Diana; Ellis, Jamey; Zerbe, Gary O; Leonard, Sherry; Stevens, Karen E; Stevens, James O; Martin, Laura; Adler, Lawrence E; Soti, Ferenc; Kem, William R; Freedman, Robert
- Abstract
The alpha7 nicotinic acetylcholine receptor gene, CHRNA7, is associated with genetic transmission of schizophrenia and related cognitive and neurophysiological sensory gating deficits. Cognitive dysfunction is responsible for significant psychosocial disability in schizophrenia. Nicotine, a low-potency agonist at the alpha7 receptor, has some positive effects on neurophysiological and neurocognitive deficits associated with schizophrenia, which suggests that more effective receptor activation might meaningfully enhance cognition in schizophrenia.
- Publication
Archives of general psychiatry, 2006, Vol 63, Issue 6, p630
- ISSN
0003-990X
- Publication type
Journal Article
- DOI
10.1001/archpsyc.63.6.630